The impact of localized prostate cancer in the elderly depends on disease aggressiveness and life expectancy. In men with localized prostate cancer, those with low-risk disease or a shorter life expectancy should be managed expectantly, whereas those with long life expectancy or more aggressive disease may benefit from curative treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Comorbidity and quality-of-life concerns are key considerations during the selection of therapeutic modalities in the elderly in localized and metastatic settings. A variety of new agents have changed the therapeutic landscape in castrate-resistant prostate cancer, but their benefits need to be considered alongside their side effects and cost.
Clinics in geriatric medicine. 2015 Oct 14 [Epub]
Kae Jack Tay, Judd W Moul, Andrew J Armstrong
Division of Urology, Duke University Medical Center, DUMC Box 103861, Durham, NC 27710, USA. , Division of Urology, Duke University Medical Center, DUMC Box 103861, Durham, NC 27710, USA. , Department of Medical Oncology, Duke University Medical Center, DUMC Box 103861, Durham, NC 27710, USA.